Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Xeris Biopharma Holdings' Other Working Capital Changes rose 342451.61% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 5555.08%. This contributed to the annual value of $1.7 million for FY2024, which is 7780.58% down from last year.
  • Xeris Biopharma Holdings' Other Working Capital Changes amounted to $5.2 million in Q3 2025, which was up 342451.61% from -$270000.0 recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Other Working Capital Changes high stood at $5.2 million for Q3 2025, and its period low was -$3.7 million during Q4 2021.
  • Over the past 5 years, Xeris Biopharma Holdings' median Other Working Capital Changes value was $684000.0 (recorded in 2023), while the average stood at $692526.3.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Other Working Capital Changes tumbled by 154724.41% in 2021, and later skyrocketed by 342451.61% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Working Capital Changes (Quarter) stood at -$3.7 million in 2021, then soared by 130.71% to $1.1 million in 2022, then dropped by 20.9% to $893000.0 in 2023, then crashed by 71.89% to $251000.0 in 2024, then surged by 1952.99% to $5.2 million in 2025.
  • Its Other Working Capital Changes was $5.2 million in Q3 2025, compared to -$270000.0 in Q2 2025 and -$1.5 million in Q1 2025.